Literature DB >> 34665662

Identifying Individualized Risk Profiles for Radiotherapy-Induced Lymphopenia Among Patients With Esophageal Cancer Using Machine Learning.

Cong Zhu1,2, Radhe Mohan2, Steven H Lin3, Goo Jun2, Ashraf Yaseen4, Xiaoqian Jiang5, Qianxia Wang1, Wenhua Cao1, Brian P Hobbs6.   

Abstract

PURPOSE: Radiotherapy (RT)-induced lymphopenia (RIL) is commonly associated with adverse clinical outcomes in patients with cancer. Using machine learning techniques, a retrospective study was conducted for patients with esophageal cancer treated with proton and photon therapies to characterize the principal pretreatment clinical and radiation dosimetric risk factors of grade 4 RIL (G4RIL) as well as to establish G4RIL risk profiles.
METHODS: A single-institution retrospective data of 746 patients with esophageal cancer treated with photons (n = 500) and protons (n = 246) was reviewed. The primary end point of our study was G4RIL. Clustering techniques were applied to identify patient subpopulations with similar pretreatment clinical and radiation dosimetric characteristics. XGBoost was built on a training set (n = 499) to predict G4RIL risks. Predictive performance was assessed on the remaining n = 247 patients. SHapley Additive exPlanations were used to rank the importance of individual predictors. Counterfactual analyses compared patients' risk profiles assuming that they had switched modalities.
RESULTS: Baseline absolute lymphocyte count and volumes of lung and spleen receiving ≥ 15 and ≥ 5 Gy, respectively, were the most important G4RIL risk determinants. The model achieved sensitivitytesting-set 0.798 and specificitytesting-set 0.667 with an area under the receiver operating characteristics curve (AUCtesting-set) of 0.783. The G4RIL risk for an average patient receiving protons increased by 19% had the patient switched to photons. Reductions in G4RIL risk were maximized with proton therapy for patients with older age, lower baseline absolute lymphocyte count, and higher lung and heart dose.
CONCLUSION: G4RIL risk varies for individual patients with esophageal cancer and is modulated by radiotherapy dosimetric parameters. The framework for machine learning presented can be applied broadly to study risk determinants of other adverse events, providing the basis for adapting treatment strategies for mitigation.

Entities:  

Mesh:

Year:  2021        PMID: 34665662      PMCID: PMC8812653          DOI: 10.1200/CCI.21.00098

Source DB:  PubMed          Journal:  JCO Clin Cancer Inform        ISSN: 2473-4276


  18 in total

1.  Youden Index and the optimal threshold for markers with mass at zero.

Authors:  Enrique F Schisterman; David Faraggi; Benjamin Reiser; Jessica Hu
Journal:  Stat Med       Date:  2008-01-30       Impact factor: 2.373

2.  Prediction of Severe Lymphopenia During Chemoradiation Therapy for Esophageal Cancer: Development and Validation of a Pretreatment Nomogram.

Authors:  Peter S N van Rossum; Wei Deng; David M Routman; Amy Y Liu; Cai Xu; Yutaka Shiraishi; Max Peters; Kenneth W Merrell; Christopher L Hallemeier; Radhe Mohan; Steven H Lin
Journal:  Pract Radiat Oncol       Date:  2019-07-29

Review 3.  Promise and pitfalls of heavy-particle therapy.

Authors:  Timur Mitin; Anthony L Zietman
Journal:  J Clin Oncol       Date:  2014-08-11       Impact factor: 44.544

4.  A novel deep learning model using dosimetric and clinical information for grade 4 radiotherapy-induced lymphopenia prediction.

Authors:  Cong Zhu; Steven H Lin; Xiaoqian Jiang; Yang Xiang; Zayne Belal; Goo Jun; Radhe Mohan
Journal:  Phys Med Biol       Date:  2020-02-04       Impact factor: 3.609

Review 5.  Natural innate and adaptive immunity to cancer.

Authors:  Matthew D Vesely; Michael H Kershaw; Robert D Schreiber; Mark J Smyth
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

6.  ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking.

Authors:  Matthew D Wilkerson; D Neil Hayes
Journal:  Bioinformatics       Date:  2010-04-28       Impact factor: 6.937

7.  Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons.

Authors:  Radhe Mohan; Amy Y Liu; Paul D Brown; Anita Mahajan; Jeffrey Dinh; Caroline Chung; Sarah McAvoy; Mary Frances McAleer; Steven H Lin; Jing Li; Amol J Ghia; Cong Zhu; Erik P Sulman; John F de Groot; Amy B Heimberger; Susan L McGovern; Clemens Grassberger; Helen Shih; Susannah Ellsworth; David R Grosshans
Journal:  Neuro Oncol       Date:  2021-02-25       Impact factor: 12.300

8.  Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy.

Authors:  Yutaka Shiraishi; Penny Fang; Cai Xu; Juhee Song; Sunil Krishnan; Eugene J Koay; Reza J Mehran; Wayne L Hofstetter; Mariela Blum-Murphy; Jaffer A Ajani; Ritsuko Komaki; Bruce Minsky; Radhe Mohan; Charles C Hsu; Brian P Hobbs; Steven H Lin
Journal:  Radiother Oncol       Date:  2017-12-14       Impact factor: 6.280

9.  Critical limitations of consensus clustering in class discovery.

Authors:  Yasin Șenbabaoğlu; George Michailidis; Jun Z Li
Journal:  Sci Rep       Date:  2014-08-27       Impact factor: 4.379

10.  Patient-Specific Lymphocyte Loss Kinetics as Biomarker of Spleen Dose in Patients Undergoing Radiation Therapy for Upper Abdominal Malignancies.

Authors:  Anirudh Yalamanchali; Hong Zhang; Ke Colin Huang; Radhe Mohan; Steven H Lin; Cong Zhu; Stuart A Grossman; Jian-Yue Jin; Susannah G Ellsworth
Journal:  Adv Radiat Oncol       Date:  2020-08-10
View more
  1 in total

1.  Whole Blood Transcriptional Fingerprints of High-Grade Glioma and Longitudinal Tumor Evolution under Carbon Ion Radiotherapy.

Authors:  Maximilian Knoll; Maria Waltenberger; Jennifer Furkel; Ute Wirkner; Aoife Ward Gahlawat; Ivana Dokic; Christian Schwager; Sebastian Adeberg; Stefan Rieken; Tobias Kessler; Felix Sahm; Laila König; Christel Herold-Mende; Stephanie E Combs; Jürgen Debus; Amir Abdollahi
Journal:  Cancers (Basel)       Date:  2022-01-28       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.